Lipohypertrophy in Acromegaly Induced by the New Growth Hormone Receptor Antagonist Pegvisomant
Authors: Pietro Maffei, Chiara Martini, Claudio Pagano, Nicola Sicolo, Francesco Corbetti
Journal: Annals of Internal Medicine (2006)

Letters15 August 2006Lipohypertrophy in Acromegaly Induced by the New Growth Hormone Receptor Antagonist PegvisomantPietro Maffei, MD, Chiara Martini, MD, Claudio Pagano, MD, Nicola Sicolo, MD, and Francesco Corbetti, MDPietro Maffei, MDFrom University School of Medicine, 35100 Padua, Italy., Chiara Martini, MDFrom University School of Medicine, 35100 Padua, Italy., Claudio Pagano, MDFrom University School of Medicine, 35100 Padua, Italy., Nicola Sicolo, MDFrom University School of Medicine, 35100 Padua, Italy., and Francesco Corbetti, MDFrom University School of Medicine, 35100 Padua, Italy.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-4-200608150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Pegvisomant (Somavert, Pfizer, New York, New York) was recently released in Italy for the treatment of acromegaly. This drug binds to growth hormone receptors and blocks the binding of endogenous growth hormone, thus decreasing serum concentrations of insulin-like growth factor I (IGF-I). Several studies reported that pegvisomant was safe and effective in more than 100 patients with acromegaly (1, 2). However, patients taking pegvisomant should be carefully followed for possible adverse effects, including increased baseline levels of growth hormone, pituitary tumor growth, hypoglycemia when taking antidiabetic drugs, functional growth hormone deficiency, and hepatitis (3). Local reactions were reported in ...References1. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-7. [PMID: 10770982] CrossrefMedlineGoogle Scholar2. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-9. [PMID: 11734231] CrossrefMedlineGoogle Scholar3. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23:623-46. [PMID: 12372843] CrossrefMedlineGoogle Scholar4. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab. 2001;86:2989-92. [PMID: 11443156] MedlineGoogle Scholar5. Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Clinical review 166: Growth hormone receptor antagonists. J Clin Endocrinol Metab. 2004;89:1503-11. [PMID: 15070905] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University School of Medicine, 35100 Padua, Italy.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPegvisomant-Induced Lipohypertrophy: Report of a Case with Histopathology Monica Marazuela , Esteban Daudén , Elena Ocón , Dolores Moure , and Lia Nattero Metrics Cited ByBody Composition Changes with Long-term Pegvisomant Therapy of AcromegalyPegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort studyCombined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studiesTherapy for AcromegalyPegvisomant in acromegaly: an updateImprovement of Insulin Injection TechniqueDoes pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experienceEfficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literatureEscape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyUse of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineMedical approach to pituitary tumorsMedical Management of Functioning Pituitary Adenoma: An UpdateMedical treatment of acromegalyClinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case seriesDG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumoursSelf-limited acute hepatotoxicity caused by pegvisomantEffectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 studyGHR Antagonist: Efficacy and SafetyACROSTUDY: the first 5 yearsSomatostatin analog and pegvisomant combination therapy for acromegalyGrowth hormone receptor polymorphism and the effects of pegvisomant in acromegalySubcutaneous lipoatrophy induced by long-term pegvisomant administrationLipodystrophy in Patients with Acromegaly Receiving PegvisomantLong-term effects of pegvisomant in patients with acromegalyEmerging drugs for acromegalyAcromegalyPegvisomantPegvisomant-Induced Lipohypertrophy: Report of a Case with HistopathologyMonica Marazuela, MD, PhD, Esteban Daudén, MD, PhD, Elena Ocón, MD, Dolores Moure, MD, and Lia Nattero, MDPegvisomant in acromegaly: Why, when, how 15 August 2006Volume 145, Issue 4Page: 310-312KeywordsAcromegalyAdipose tissueAttentionDrugsFatsGrowth hormoneInsulin-like growth factorsMagnetic resonance imagingPatient advocacyUltrasound imaging ePublished: 15 August 2006 Issue Published: 15 August 2006 CopyrightCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...